Ocular Melanoma Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Ocular Melanoma Epidemiology Forecast Report Coverage

Expert Market Research's “Ocular Melanoma Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of ocular melanoma. It projects the future incidence and prevalence rates of ocular melanoma cases across various populations. The study covers age, gender, and type as major determinants of the ocular melanoma population. The report highlights patterns in the prevalence of ocular melanoma over time and projects future trends based on multiple variables.

Ocular Melanoma Understanding: Disease Overview

Ocular melanoma is a rare but aggressive form of eye cancer arising from melanocytes within the uveal tract, including the iris, ciliary body, and choroid. It represents the most common primary intraocular malignancy in adults. Risk factors include light eye color, UV exposure, and genetic mutations such as BAP1. Patients may present with blurred vision, visual field loss, or photopsia. Early detection is critical due to high metastatic potential, particularly to the liver. Advances in diagnostics support improved outcomes in ocular melanoma symptoms evaluation and staging and clinical management protocols.

Ocular Melanoma Epidemiology Perspective

The ocular melanoma epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the ocular melanoma epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for ocular melanoma and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Wu et al., 2023, worldwide ocular melanoma incidence exceeds 8.0 per million person-years in Northern Europe and Oceania, while remaining below 2.0 per million in Asia and Africa.
• As per the Aronow et al., 2025, the US mean age-adjusted uveal melanoma incidence from 1975 to 2020 was 5.6 per million, with peak incidence observed among older adults aged 70-79 years.
• According to Aronow et al., 2025, males exhibited significantly higher age-adjusted uveal melanoma incidence at 6.3 per million compared with females at 5.0 per million in the United States from 1975 to 2020.
• As per Zahra et al., 2025, SEER analysis (2000-2021) revealed uveal melanoma predominantly affected Caucasians (91.25%), followed by Hispanics (5.6%), Asian/Pacific Islanders (1.34%), Black individuals (0.64%), and American Indians (0.27%).

Read more about this report - Request a Free Sample

Country-wise Ocular Melanoma Epidemiology

The ocular melanoma epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Ocular melanoma epidemiology is supported by robust population-based data from both the United States and Germany, reflecting consistent incidence patterns and demographic trends. In the United States, Aronow et al. (2025) reported 5,563 cases with an incidence of 5.6 per million, showing higher rates among males. In Germany, Alfaar et al. (2022) documented 3,654 cases with an incidence of 6.41 per million, including notable regional variation. Collectively, these findings enhance understanding of disease burden and support improved clinical planning and management strategies.

Ocular Melanoma: Treatment Overview

Ocular melanoma management focuses on tumor control, vision preservation, and metastasis prevention using a multimodal approach. Treatments include plaque brachytherapy, proton beam radiotherapy, laser photocoagulation, and enucleation in advanced cases. Systemic therapies and immunotherapy are considered for metastatic disease, particularly liver-directed therapies. Molecular profiling helps guide personalized care strategies. Regular surveillance is essential due to recurrence risk. Ongoing clinical trials are improving survival outcomes. Innovations in ocular melanoma treatment are enhancing targeted therapy options and reducing ocular morbidity while improving long-term patient prognosis and quality of life globally.

Key Questions Answered

• What are the key findings of ocular melanoma epidemiology in the 8 major markets?
• What will be the total number of patients with ocular melanoma across the 8 major markets during the forecast period?
• What was the country-wise ocular melanoma epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of ocular melanoma patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of ocular melanoma during the forecast period of 2026-2035?
• What are the currently available treatments for ocular melanoma?
• What are the disease risks, signs, symptoms, and unmet needs of ocular melanoma?

Scope of the Ocular Melanoma Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of ocular melanoma based on several factors.
• Ocular Melanoma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The ocular melanoma report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Intraocular Melanoma Treatment Market

Melanoma Market

Melanoma Epidemiology Forecast